PASADENA, California — BioVinc, LLC announced today that its research manuscript, “Effects of Hydroxybisphosphonate-Conjugated Sitafloxacin on Fracture Healing and Skeletal Growth in Mice,” has been selected as the cover article in the February issue of JBMR Plus, a peer-reviewed journal of the American Society for Bone and Mineral Research.
The study evaluates the biological effects of OsteoFloxacin, BioVinc’s lead drug candidate designed to selectively deliver antimicrobial therapy to infected bone tissue. Chronic musculoskeletal infections—including osteomyelitis and prosthetic joint infections—remain among the most difficult infections to treat because conventional antibiotics often fail to reach bacteria embedded deep within bone and biofilm structures.
BioVinc would also like to acknowledge its close collaboration and the many contributions from Professor Edward Schwarz and his team at the University of Rochester Medical School, who have provided much of the key evidence to demonstrate the outstanding potential of our drug candidate, OsteoFloxacin, for the treatment of severe osteomyelitis, an important unmet medical need.
Using established mouse models, researchers assessed whether OsteoFloxacin affects fracture healing, skeletal growth, or bone mechanical strength. The results demonstrated that treatment did not impair bone healing or skeletal development, supporting the safety profile of this targeted therapeutic strategy.
Selection of the manuscript as a cover article highlights growing interest in bone-targeted therapeutic approachescapable of concentrating drug activity directly at sites of skeletal disease. The findings provide important preclinical evidence supporting continued development of OsteoFloxacin and reinforce the broader potential of BioVinc’s bone-targeted therapeutic platform.
BioVinc is developing a new class of bone-targeted anti-infective therapies designed to concentrate antibiotics at sites of infection while minimizing systemic exposure, with the goal of improving outcomes for patients suffering from serious skeletal infections.
The full article is available at:
https://doi.org/10.1093/jbmrpl/ziaf195
